Suppr超能文献

HealosMP52骨诱导性骨移植材料用于绵羊腰椎经横突间器械辅助融合术的评估

Evaluation of HealosMP52 osteoinductive bone graft for instrumented lumbar intertransverse process fusion in sheep.

作者信息

Kim Daniel H, Jahng Tae A, Fu Tsai-Sheng, Zhang Ho-Yeol, Novak Shannon A

机构信息

Department of Neurosurgery, Stanford University Medical Center, Stanford, California 94305-5327, USA.

出版信息

Spine (Phila Pa 1976). 2004 Dec 15;29(24):2800-8. doi: 10.1097/01.brs.0000148155.79353.ac.

Abstract

STUDY DESIGN

HealosMP52 was evaluated in a sheep model of instrumented lumbar intertransverse process spine fusion and compared to autogenous bone graft.

OBJECTIVES

To determine the long-term efficacy and safety of HealosMP52 as a bone graft substitute in posterolateral instrumented spinal fusion.

SUMMARY OF BACKGROUND DATA

Although the standard intertransverse fusion method employs autogenous iliac crest bone, autograft has certain limitations. HealosMP52, an osteoinductive bone graft material, can facilitate noninstrumented posterolateral spine fusion in rabbits and nonhuman primates, but the long-term outcome of such fusions has not been evaluated.

METHODS

Eleven skeletally mature, female sheep were instrumented with pedicle screws and rods at L2-L3 and L5-L6. Each animal was treated with autograft bone at one fusion level and HealosMP52 at the other. At 6 and 12 months after surgery, bone formation was measured on contact microradiographs and by backscattered electron imaging. Bone core biopsies taken from 6-month and 12-month specimens were evaluated histologically for pathology indicative of osteosarcoma.

RESULTS

Grossly, all autograft- and HealosMP52-treated levels showed stable fusions at 6 and 12 months. HealosMP52 and autograft treatments resulted in equivalent mean percent bone volumes within fusion bodies; similar values were observed at 6 and 12 months. Fusion bodies contained cortical and trabecular bone with osteoid seams and fatty marrow, and fusion masses showed maturation from 6 to 12 months. HealosMP52 treatment was not associated with implant migration, ectopic bone formation, or pathologic abnormality. No histologic evidence of osteosarcoma was seen on bone core biopsies.

CONCLUSIONS

This long-term assessment of the use of HealosMP52 in posterolateral instrumented spine fusion indicates that HealosMP52 possesses safe and efficacious bone grafting properties and can potentially serve as anosteoinductive alternative to autograft bone.

摘要

研究设计

在绵羊腰椎横突间器械辅助脊柱融合模型中对HealosMP52进行评估,并与自体骨移植进行比较。

目的

确定HealosMP52作为后路器械辅助脊柱融合中骨移植替代物的长期疗效和安全性。

背景数据总结

尽管标准的横突间融合方法采用自体髂嵴骨,但自体骨移植有一定局限性。HealosMP52是一种骨诱导性骨移植材料,可促进兔和非人灵长类动物的非器械辅助后路脊柱融合,但此类融合的长期结果尚未得到评估。

方法

对11只骨骼成熟的雌性绵羊在L2-L3和L5-L6节段植入椎弓根螺钉和棒。每只动物在一个融合节段用自体骨移植治疗,在另一个融合节段用HealosMP52治疗。在术后6个月和12个月,通过接触式显微放射摄影和背散射电子成像测量骨形成。对取自6个月和12个月标本的骨芯活检组织进行组织学评估,以检测骨肉瘤的病理特征。

结果

大体观察,所有接受自体骨移植和HealosMP52治疗的节段在6个月和12个月时均显示融合稳定。HealosMP52和自体骨移植治疗在融合体内产生了相当的平均骨体积百分比;在6个月和12个月时观察到相似的值。融合体包含皮质骨和小梁骨,伴有类骨质缝和脂肪骨髓,融合块在6至12个月间显示出成熟过程。HealosMP52治疗与植入物移位、异位骨形成或病理异常无关。在骨芯活检中未发现骨肉瘤的组织学证据。

结论

对HealosMP52用于后路器械辅助脊柱融合的长期评估表明,HealosMP52具有安全有效的骨移植特性,有可能作为自体骨移植的骨诱导替代物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验